EP Patent

EP2987490A1 — Crystalline freebase forms of a biphenyl compound

Assigned to Theravance Biopharma R&D IP LLC · Expires 2016-02-24 · 10y expired

What this patent protects

The invention provides a crystalline freebase form of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using…

USPTO Abstract

The invention provides a crystalline freebase form of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester. The invention also provides pharmaceutical compositions comprising the crystalline freebase or prepared using the crystalline freebase; processes and intermediates for preparing the crystalline freebase; and describes methods of using the crystalline freebase to treat a pulmonary disorder.

Drugs covered by this patent

Patent Metadata

Patent number
EP2987490A1
Jurisdiction
EP
Classification
—
Expires
2016-02-24
Drug substance claim
No
Drug product claim
No
Assignee
Theravance Biopharma R&D IP LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.